CMS Memorandum Outlines Enhanced Oversight and Enforcement of Nursing Home Non-Improving Late Adopters
The National Partnership to Improve Dementia Care in Nursing Homes (the National Partnership) has a mission to deliver health care that is person centered, comprehensive and interdisciplinary with a specific focus on protecting residents from being prescribed antipsychotic medications unless there is a valid, clinical indication and a systematic process to evaluate each individual’s need.
Since 2011, the Centers for Medicare & Medicaid Services (CMS) has seen a reduction of 38.9 percent in long stay nursing home residents who were receiving an antipsychotic medication. Despite the success of the National Partnership, CMS identified approximately 1,500 facilities that had not improved their antipsychotic medication utilization rates for long-stay nursing home residents, referred to as late adopters. In December 2017, CMS notified these facilities of this identification.
CMS intends to continue to expand its efforts to decrease the use of antipsychotic medication by adopting a two-pronged approach. The first approach will involve enhanced oversight and enforcement actions, while the second approach will focus on outreach with corporations that own or operate significant numbers of late adopter facilities. Both approaches expect to improve dementia care and reduce the inappropriate use of psychotropic medications and chemical restraints for nursing homes identified as late adopters. The enhanced oversight and enforcement approach will focus two subgroups of these late adopter nursing homes which have had a prior history of noncompliance citations with specific federal requirements related to antipsychotic medication use and dementia care.
Follow the link below to review the CMS memorandum in its entirety. Included with today’s notice are example policies related to the use of restraints – including chemical restraints – in the long-term care setting.
Want to read the full alert and receive alert emails?